Author | Robert Z. Orlowski, MD, PhD


The Future of Proteasome Inhibitors in Relapsed/Refractory Multiple Myeloma

November 15, 2011

Bortezomib (Velcade), the first-in-class inhibitor of the proteasome,[1] or multicatalytic proteinase complex,[2] was originally found to be active against relapsed and relapsed/refractory multiple myeloma as a single agent in phase I through III clinical trials.[3-6